By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Synthon Pharmaceuticals, Ltd. 

6330 Quadrangle Drive, Suite 305

Chapel Hill  North Carolina  27514  U.S.A.
Phone: 919-493-6006 Fax: 919-493-6104



Company News
Synthon Pharmaceuticals Obtains Approval For Glatiramer Acetate 20 mg/mL In Europe 4/12/2016 10:03:07 AM
Synthon Pharmaceuticals Announces Successful Outcomes From The Open-Label Extension Of The Phase III GATE Study Of Synthon’s Glatiramer Acetate 4/28/2015 9:24:05 AM
Synthon Pharmaceuticals Announces Filing Of Glatiramer Acetate 40 Mg/Ml ANDA Containing A Paragraph IV Certification 10/9/2014 1:52:36 PM
Synthon Pharmaceuticals’s Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADC 4/2/2014 9:31:05 AM
Synthon Pharmaceuticals Announces Successful Outcome Of The Phase 3 GATE Study With Its Generic Glatiramer Acetate 3/27/2014 9:25:12 AM
Synthon Pharmaceuticals Enters Into Global License Agreement With Amgen (AMGN) and Watson Pharmaceuticals, Inc. (WPI) for Biosimilar Trastuzumab 7/18/2012 9:18:09 AM
Synthon Pharmaceuticals Appoints Paul Roos as Chief Financial Officer 5/7/2012 10:20:40 AM
Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for Trastuzumab 3/22/2012 1:30:10 PM
Perrigo Company (PRGO) and its Partner Synthon Pharmaceuticals Launch Levocetirizine Solution - Generic Equivalent to Xyzal(R) Oral Solution 11/8/2011 6:02:57 AM
Breckenridge Pharmaceutical, Inc. and Synthon Pharmaceuticals Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation With Takeda Pharmaceutical Co. Ltd. (TKDG.DE) 5/16/2011 9:58:13 AM